The recent display of a new product by
Varian Medical System
) at the 54th annual meeting of the American Society for
Radiation Oncology (ASTRO) should further boost the positive
trend demonstrated by VAR's stock over the last couple of weeks.
Varian's latest RapidPlan knowledge-based software provides
standard of care models to clinicians to use as a baseline for
formulating complex intensity-modulated radiotherapy (IMRT)
treatment plans for their patients. However, the product from the
company's Oncology Systems business is yet to receive U.S. Food
and Drug Administration (FDA) approval and is not yet available
The RapidPlan tool is integrated within Varian's Eclipse
treatment planning system, used for planning all types of
external beam radiotherapy. The software helps automate an
important part of the treatment planning process, thereby
improving the quality and efficiency of care.
Similar products offered by the company include the RapidArc
technology and the Smart Segmentation knowledge-based tool. Based
on the cost effectiveness of the new softwares, management plans
to create more knowledge-driven solutions for the entire oncology
Recently, VAR completed the first two planned installations of
its Edge Radiosurgery Suite in Europe and the U.S. The
Radiosurgery Suite is designed to perform advanced radiosurgery
using real-time tumor tracking technology and motion management
Varian will also launch The Edge Advisory Board to help
clinicians perform the procedures. Through this board, VAR will
provide clinical education by partnering with leaders in
radiosurgery, including neuro- and thoracic surgeons as well as
Varian is poised to increase its global market share in the
radiation oncology market as international markets are still
under-equipped to address the growing incidence of cancer. Last
month, the company received an order for 20 TrueBeam machines
from NHS Supply Chain for NHS hospitals across the U.K.
VAR has a Zacks Rank #2 (Buy). Other medical instruments stocks
Delcath Systems, Inc.
Echo Therapeutics, Inc.
) are worth a look at the moment. All of them carry a Zacks Rank
CYNOSURE INC-A (CYNO): Free Stock Analysis
DELCATH SYS INC (DCTH): Free Stock Analysis
ECHO THERAPEUT (ECTE): Free Stock Analysis
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.